Polpharma Biologics Group Announces That Its Joint Venture Bioeq Has Submitted a Biologics License Application (BLA) for Biosimilar Ranibizumab to the U.S. Food and Drug Administration (FDA)
6.8.2021 12:13:00 EEST | Business Wire | Press release
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®).
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) used to treat various types of macular-degenerative diseases such as neovascular (wet) age-related macular degeneration, diabetic retinopathy, macular edemas and myopic choroidal neovascularization. Worldwide, at least 25 to 30 million people are affected by age-related macular degeneration. The launch of a biosimilar Ranibizumab can increase market competition, reduce cost and expand patient access with proven analytical and clinical similarity to the original product. It works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.
Subject to FDA's approval of this BLA, the product will be exclusively commercialized by Coherus BioSciences, Inc. in the United States.
Said submission represents the most recent milestone for Bioeq's ranibizumab biosimilar program and compliments marketing authorization applications submitted to EMA and UK MHRA already in July this year.
Dr Joerg Windisch, CEO of the Polpharma Biologics Group, commented:
“The submission of a BLA to the FDA is a major milestone for any therapeutic and brings hope to patients across the US. This announcement carries a tangible promise of treatment choice and improved access to those who suffer from debilitating vision loss, including age-related macular degeneration. This is another representation of our commitment to providing safe and effective medicines to patients.”
1) Lucentis ® is a registered trademark of Genentech Inc.
About Ranibizumab biosimilar
The Ranibizumab biosimilar, previously designated as FYB201 (and also known as CHS-201), has been originally licensed from Formycon AG (FRA: FYB/ WKN A1EWVY), a leading German biosimilars company, and subsequently developed by Bioeq AG, a joint venture between Polpharma Biologics and Santo Holding AG (Strüngmann Group). Phase III clinical trials for FYB201 have clinically demonstrated that the efficacy of FYB201 in patients with nAMD is comparable to that of Lucentis®.
About biosimilars
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.
About Polpharma Biologics Group
The Polpharma Biologics Group creates quality biosimilars with a passion to improve lives of patients. The group has built an extensive and growing pipeline of biosimilars to treat a number of medical conditions across major therapeutic areas. Several of these biosimilar assets have already been commercially partnered with the world’s largest biopharmaceutical companies.
The group operates a network of state-of-the-art development and manufacturing facilities across Europe, actively investing in technology, people and know-how, employing over 800 specialists from around the globe.
Learn more at www.polpharmabiologics.com
About Bioeq
Bioeq is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210806005187/en/
Contact information
Joseph Reeds
Head of Marketing, Polpharma Biologics
Joseph.reeds@polpharmabiologics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sofinnova Partners Promotes Javier Nunez-Vicandi to Partner, Strengthening Its Digital Medicine Strategy2.11.2026 09:00:00 EET | Press release
Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, today announced the promotion of Javier Nunez-Vicandi to Partner. He joins Edward Kliphuis and Simon Turner in the firm’s Digital Medicine strategy, which invests in startups working at the intersection of biology, data, and AI. Since joining Sofinnova in 2022, Nunez-Vicandi has played a key role in the development of the firm's Digital Medicine strategy and broader AI efforts. He helped shape key AI investment theses within the Digital Medicine Strategy and is an observer on the boards of Latent Labs, Bioptimus, Cure51, Deepc, and Kiro. Javier has also recently led an investment that remains in stealth. Within Sofinnova's broader AI efforts, Javier co-led the project that created Sofia, Sofinnova's proprietary AI platform, which supports investments and scientific analysis. As part of this effort, Javier helped lead the firm's collaborations with AWS and NVIDI
SES to Supply Finnair with Ground-like Connectivity Experience in the Skies2.11.2026 09:00:00 EET | Press release
SES today announced a new agreement with Finnair, Finland's flagship airline, to equip 18 E195-E2s with multi-orbit in-flight connectivity, enabling Finnair’s customers to enjoy fast, reliable internet access throughout their journey. Under the agreement, the Embraer E2 aircraft, which will be line-fitted at Embraer, will be equipped with SES’s electronically steered array antenna (ESA) offering reliable connectivity to the SES multi-orbit network, combining SES’s geostationary (GEO) satellite services with low-earth orbit (LEO) capacity from its partner Eutelsat. The first connected aircraft is expected to enter service in 2027. “Inflight Wi-Fi is a core part of the travel experience,” said Blane Boynton, Senior Vice President Aviation at SES. “SES’s multi-orbit network delivers the reliability, performance and flexibility airlines need today while providing a clear path for future growth. This agreement is another testament to the growing confidence leading airlines are placing in ou
Speech Processing Solutions Launches Philips SpeechLive Legal Direct and Philips SpeechLive Professional Direct with Real-Time Speech Recognition Directly at Cursor2.11.2026 09:00:00 EET | Press release
Speech Processing Solutions (SPS), the global leader in professional dictation and transcription solutions sold under the Philips brand, today announced the launch of Philips SpeechLive Legal Direct and Philips SpeechLive Professional Direct. The two solutions allow legal and other professionals to dictate into supported desktop applications, with recognized text appearing as they speak. They are designed both for organizations adopting professional speech recognition for the first time and for customers moving from established or end-of-life speech recognition solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029365830/en/ Philips SpeechLive Legal Direct – legal speech recognition, directly at cursor With support of 29 voice commands across 19 languages, these new solutions combine familiar dictation practices with commands covering navigation, selection, editing, formatting, lists and help functions. Professiona
Thales Selected to Deliver Next-Generation Mine-Hunting Capability for the U.S. Navy2.11.2026 08:00:00 EET | Press release
Thales’ subsidiary Advanced Acoustic Concepts (AAC), a U.S.-based provider of undersea warfare solutions, was awarded a $53.9 million U.S. Navy contract to produce and deliver two integrated Remote Mine Hunting (RMH) modules and accompanying engineering support. The award includes options for additional modules that could increase the total cumulative contract value to approximately $196.2 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261101304707/en/ Sonar ©Thales The RMH solution supports the Navy's Mine Countermeasures (MCM) mission through the proven “Find, Fix and Finish” approach to defeating mine threats. The capability enables sailors to remotely detect, locate and classify undersea mines, while operating from safer stand-off distances, enhancing mission effectiveness and reducing risk in contested maritime environments. “The ability to counter undersea mine threats remains fundamental to maritime security
Uptime Institute and Indonesia Ministry of Communication and Digital Affairs (KOMDIGI) Sign Letter of Intent (LOI) to Support Data Center Policy, Governance, and Industry Development2.11.2026 07:04:00 EET | Press release
Uptime Institute, the Global Digital Infrastructure Authority, and the Ministry of Communication and Digital Affairs (Komdigi) today announced the signing of a Letter of Intent (LOI) to explore collaboration aimed at strengthening Indonesia's data center ecosystem through policy development, governance frameworks, operational excellence, security, sustainability, and workforce capability development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261101628182/en/ Uptime Institute and KOMDIGI sign LOI. The Letter of Intent reflects a shared interest in exploring international best practices that may support the development of reliable, secure, efficient, and sustainable digital infrastructure aligned with Indonesia's national priorities and regulatory framework. The LOI was signed by Mustapha Louni, Chief Business Officer, Uptime Institute, and Wayan Toni Supriyanto, Director General of Digital Infrastructure, Indonesia's Min
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom